Recursion Pharmaceuticals, Inc. RXRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total equity?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total equity of $1.02B in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total equity increased by 9.7% year-over-year, from $933.95M to $1.02B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total equity has grown at a 40.5% compound annual growth rate (CAGR), from -$206.29M to $1.13B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.